Module 2: Regulatory Strategy for a New Active Substance: Non-clinical

11 - 13 February 2025

Lincoln Plaza Hotel, 2 Lincoln Plaza, London E14 9BN

Module Leader(s): Lesley Reeve and Andy Gibbs

Date: Tuesday 11th February



Time (CET)	Activity	Speaker
13.30 - 14.00	Lunch and registration	
14:05 - 14.20	Welcome & Introduction to Module	Lesley Reeve Module Leader
14.25 - 15.15	Lecture 1: Non-clinical Studies in Drug Development	Elisa Passini NC3Rs
15.20 - 16.10	Lecture 2: Selection of a Candidate Compound: Studies to Identify Likely Candidates	Tom Hammond AstraZeneca
16.10 - 16.30	Refreshment Break	
16.30 - 17.15	Lecture 3: Safety Pharmacology Studies	Andrea Greiter-Wilke Roche, Switzerland
17.30	Close of day 1	

Module 2: Regulatory Strategy for a New Active Substance: Non-clinical 11 – 13 February 2025

Lincoln Plaza Hotel, 2 Lincoln Plaza, London E14 9BN



Date: Wednesday 12th February

Time (CET)	Activity	Speaker
09.00 - 10.00	Lecture 4: Introduction to Pharmacokinetics and Application of Drug Development	Peter Kilford Simulations Plus
10.05 – 10.25	Refreshment Break	
10.25 - 11.25	Lecture 5: General Toxicology Studies	Lesley Reeve Fortrea
11.30 - 12.20	Lecture 6: Genotoxicity and Carcinogenicity	Lesley Reeve Fortrea
12.25 - 13.25	Lunch	
13.30 - 14.30	Lecture 7 : Reproductive Toxicology Testing – What and Why	Jane Stewart Apconix
14.35 - 14.55	Lecture 8: Environmental Risk Assessment	Sarah Bull Tara Consulting
15.00 - 15.45	Refreshment Break	
15.50 - 18.30	Case Study and feedback	Lesley Reeve and Andy Gibbs Module Leaders

Module 2: Regulatory Strategy for a New Active Substance: Non-clinical

11 - 13 February 2025

Lincoln Plaza Hotel, 2 Lincoln Plaza, London E14 9BN



Date: Thursday 13th February

09.00 - 09.45	Lecture 9: Toxicology Support for Paediatric Development	Paul Baldrick Fortrea
09.50 - 10.40	Lecture 10: Overall Assessment of the Non-clinical Package and Strategic Planning	Lesley Reeve Fortrea
10.40 - 11.00	Refreshment Break	
11.00 - 11.50	Lecture 11: Specific Non-clinical Considerations Associated with Biotechnology Products	Andy Gibbs LabCorp
11.55 - 12.45	Lecture 12: Specific Non-clinical Considerations Associated with Cell and Gene Therapy Products	Michaela Sharpe Moare Solutions Ltd
12.45 - 13.45	Lunch	
13.45 - 15.45	Lecture 13: Agency Review Process / Data Presentation Problems	Julianne Berrie MHRA
15.45 - 16.00	Close of Module	